Research ExplorerPublicationsWhat Should Clinicians Tell Patients about Placebo and Noceb...

What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus

Standard

What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus. / Evers, Andrea W M; Colloca, Luana; Blease, Charlotte; Gaab, Jens; Jensen, Karin B; Atlas, Lauren Y; Beedie, Chris J; Benedetti, Fabrizio; Bingel, Ulrike; Büchel, Christian; Bussemaker, Jet; Colagiuri, Ben; Crum, Alia J; Finniss, Damien G; Geers, Andrew L; Howick, Jeremy; Klinger, Regine; Meeuwis, Stefanie H; Meissner, Karin; Napadow, Vitaly; Petrie, Keith J; Rief, Winfried; Smeets, Ionica; Wager, Tor D; Wanigasekera, Vishvarani; Vase, Lene; Kelley, John M; Kirsch, Irving; Consortium of Placebo Experts.

In: PSYCHOTHER PSYCHOSOM, Vol. 90, No. 1, 2021, p. 49-56.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Evers, AWM, Colloca, L, Blease, C, Gaab, J, Jensen, KB, Atlas, LY, Beedie, CJ, Benedetti, F, Bingel, U, Büchel, C, Bussemaker, J, Colagiuri, B, Crum, AJ, Finniss, DG, Geers, AL, Howick, J, Klinger, R, Meeuwis, SH, Meissner, K, Napadow, V, Petrie, KJ, Rief, W, Smeets, I, Wager, TD, Wanigasekera, V, Vase, L, Kelley, JM, Kirsch, I & Consortium of Placebo Experts 2021, 'What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus', PSYCHOTHER PSYCHOSOM, vol. 90, no. 1, pp. 49-56. https://doi.org/10.1159/000510738

APA

Evers, A. W. M., Colloca, L., Blease, C., Gaab, J., Jensen, K. B., Atlas, L. Y., Beedie, C. J., Benedetti, F., Bingel, U., Büchel, C., Bussemaker, J., Colagiuri, B., Crum, A. J., Finniss, D. G., Geers, A. L., Howick, J., Klinger, R., Meeuwis, S. H., Meissner, K., ... Consortium of Placebo Experts (2021). What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus. PSYCHOTHER PSYCHOSOM, 90(1), 49-56. https://doi.org/10.1159/000510738

Vancouver

Evers AWM, Colloca L, Blease C, Gaab J, Jensen KB, Atlas LY et al. What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus. PSYCHOTHER PSYCHOSOM. 2021;90(1):49-56. https://doi.org/10.1159/000510738

Bibtex

@article{418e099be7954de0b4a34d4af975c5b2,
title = "What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus",
abstract = "INTRODUCTION: Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments.OBJECTIVE: There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information.METHODS: Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients.RESULTS: There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities.CONCLUSIONS: The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients' needs, and on developing standardized disclosure training modules for clinicians.",
author = "Evers, {Andrea W M} and Luana Colloca and Charlotte Blease and Jens Gaab and Jensen, {Karin B} and Atlas, {Lauren Y} and Beedie, {Chris J} and Fabrizio Benedetti and Ulrike Bingel and Christian B{\"u}chel and Jet Bussemaker and Ben Colagiuri and Crum, {Alia J} and Finniss, {Damien G} and Geers, {Andrew L} and Jeremy Howick and Regine Klinger and Meeuwis, {Stefanie H} and Karin Meissner and Vitaly Napadow and Petrie, {Keith J} and Winfried Rief and Ionica Smeets and Wager, {Tor D} and Vishvarani Wanigasekera and Lene Vase and Kelley, {John M} and Irving Kirsch and Consortium of Placebo Experts",
note = "{\textcopyright} 2020 The Author(s) Published by S. Karger AG, Basel.",
year = "2021",
doi = "10.1159/000510738",
language = "English",
volume = "90",
pages = "49--56",
journal = "PSYCHOTHER PSYCHOSOM",
issn = "0033-3190",
publisher = "S. Karger AG",
number = "1",

}

RIS

TY - JOUR

T1 - What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus

AU - Evers, Andrea W M

AU - Colloca, Luana

AU - Blease, Charlotte

AU - Gaab, Jens

AU - Jensen, Karin B

AU - Atlas, Lauren Y

AU - Beedie, Chris J

AU - Benedetti, Fabrizio

AU - Bingel, Ulrike

AU - Büchel, Christian

AU - Bussemaker, Jet

AU - Colagiuri, Ben

AU - Crum, Alia J

AU - Finniss, Damien G

AU - Geers, Andrew L

AU - Howick, Jeremy

AU - Klinger, Regine

AU - Meeuwis, Stefanie H

AU - Meissner, Karin

AU - Napadow, Vitaly

AU - Petrie, Keith J

AU - Rief, Winfried

AU - Smeets, Ionica

AU - Wager, Tor D

AU - Wanigasekera, Vishvarani

AU - Vase, Lene

AU - Kelley, John M

AU - Kirsch, Irving

AU - Consortium of Placebo Experts

N1 - © 2020 The Author(s) Published by S. Karger AG, Basel.

PY - 2021

Y1 - 2021

N2 - INTRODUCTION: Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments.OBJECTIVE: There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information.METHODS: Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients.RESULTS: There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities.CONCLUSIONS: The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients' needs, and on developing standardized disclosure training modules for clinicians.

AB - INTRODUCTION: Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments.OBJECTIVE: There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information.METHODS: Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients.RESULTS: There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities.CONCLUSIONS: The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients' needs, and on developing standardized disclosure training modules for clinicians.

U2 - 10.1159/000510738

DO - 10.1159/000510738

M3 - SCORING: Journal article

C2 - 33075796

VL - 90

SP - 49

EP - 56

JO - PSYCHOTHER PSYCHOSOM

JF - PSYCHOTHER PSYCHOSOM

SN - 0033-3190

IS - 1

ER -